Trials / Active Not Recruiting
Active Not RecruitingNCT06632106
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
In Which Tumor Burden Range Does Advanced Hepatocellular Carcinoma Patients Benefit More from Hepatic Arterial Infusion Chemotherapy Plus Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors Than Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors? a Multi-center, Retrospective, Propensity Score Matching Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 97 (actual)
- Sponsor
- First Hospital of China Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
Conditions
- Hepatic Arterial Infusion Chemotherapy
- Tyrosine Kinase Inhibitor
- Immune Checkpoint Inhibitors
- Hepatocellular Carcinoma (HCC)
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | hepatic artery infusion chemotherapy | Hepatic arterial infusion chemotherapy including FOLFOX and RALOX |
| DRUG | Tyrosine kinase inhibitor (TKIs) | TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab |
| DRUG | Immune Checkpoint Inhibitors | ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab |
Timeline
- Start date
- 2024-08-16
- Primary completion
- 2025-01-30
- Completion
- 2025-05-30
- First posted
- 2024-10-08
- Last updated
- 2024-10-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06632106. Inclusion in this directory is not an endorsement.